Loss of heterozygosity for Rb locus and pRb immunostaining in laryngeal cancer: a clinicopathologic, molecular and immunohistochemical study. by Pietruszewska, Wioletta et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2008:46(4): 479 (479-485) 
doi: 10.2478/v10042-008-0076-6
Introduction 
By compromising the normal mechanisms of speech,
laryngeal cancer may cause a considerable morbidity
despite its obvious effects on health and survival.
Despite the high occurrence in men in Poland, rela-
tively little is known about its molecular biology.
There is a need for a deeper understanding of this dis-
ease as the 5-year survival rate for head and neck
patients has not changed significantly over more than
20 years [1]. Although several risk factors for the
development of laryngeal cancer have been identified,
such as smoking and alcohol consumption, the molec-
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Abstract: Several risk factors for the development of laryngeal cancer have been identified, such as smoking and alcohol
consumption, but the molecular mechanisms related to the carcinogenesis in the larynx remain under investigation. In this
context, deregulations of the cell-cycle-controling mechanisms, Rb-pathway in particular, have been suggested to be involved
in the pathogenesis of laryngeal carcinoma. Our purpose was to investigate 13q14 LOH and the expression of Rb protein and
their possible prognostic value in laryngeal cancer. The group of 67 patients with laryngeal cancer, surgically treated with min-
imum 5 years observation, was multi-variously analysed. LOH for Rb was investigated by PCR-based techniques using two
microsatellite markers, D13S263 and D13S126, flanking the Rb locus. Amplification products from each polymorphism were
fractionated by denaturing gel electrophoresis and detected by audioradiography. Immunohistochemical staining of paraffin
specimens of laryngeal cancers was supervised by the use of monoclonal mouse antibodies IgG1 (Anti-Human Retinoblastoma
Gene Product of Dako) in dilution of 1:50. Inactivation of Rb protein was assumed to represent the expression in ≤10 % tumour
cells. The results of each examined individual factor were compared with clinicopathologic features and the results were sta-
tistically transformed (Chi-square test with Yates' correction, Mann-Whitney test). The Kaplan and Meier model was used for
overall and disease free survival curves. Only p value of less than 0,05 was considered significant. 13q14 LOH was detected
in 7/67 (10,4%) of informative tumours. No correlations were found between Rb genetic alteration (LOH) and gender, age,
TNM staging, histological differentiation, nodal and local recurrences (p>0.05). There was a strong association between the
loss of Rb and supraglottic localisation of tumour in the larynx (p<0.01). By univariate analysis 13q14 LOH proved to be sig-
nificantly related to the overall survival whereas it was not related to the quicker relapse (p=0.01, p>0.05 respectively). The
genetic data were correlated with the expression of the Rb protein (p=0.001). All tumours with Rb-LOH were immunohisto-
chemically Rb-negative. Inactivation of Rb protein was observed in 9/67 cases (13.49%) and was significantly correlated with
the polymorphism of cancer cells, but not with the histological grading. We also found the correlation between reduction of Rb
protein and the size of primary tumour (T) (p=0.03) and local recurrence (p=0.035). There was no significant dependence
between the level of Rb protein and other histopathological and clinical features (p>0.05). To conclude, analysis of 13q14 LOH
enables the assessment of biology of laryngeal cancer and it can be a prognostic factor in overall survival. Immunohistochem-
ical analysis of Rb protein expression in neoplastic cells made it easier to evaluate the mechanisms of cancerogenesis in laryn-
geal cancer and is closely related to genetic alteration in Rb locus.
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ular mechanisms related to the carcinogenesis in the lar-
ynx remain under investigation. In this context, deregu-
lations of the cell-cycle-controlling mechanisms, Rb-
pathway in particular, have been suggested to be
involved in the pathogenesis of laryngeal carcinoma.
Carcinogenesis is a multistep process, which leads to
the accumulation of several genetic alterations, includ-
ing the inhibition of tumour suppressor genes (TSGs)
and activation of oncogenes. The loss of inactivation of
TSGs plays an important role in the development and
progression of many solid tumours. There are more than
20 types of TSGs which are associated with human can-
cer. The inactivation of some tumour suppressor genes
manifest itself through the loss of heterozygosity at
nearby mapping markers. Studies on the loss of het-
erozygosity (LOH) have been carried out to identify
sites harbouring tumour suppressor genes involved in
tumour initiation or progression. Inactivation of these
genes appears to have diagnostic and prognostic signif-
icance in some types of tumours. Molecular genetic and
immunohistochemical tools based on suppressor inacti-
vation might be very helpful in the treatment planning
[2]. Gene products involved in the process of tumorige-
nesis and metastasis are expected to play a role in pro-
liferation, migration and cell adhesion, and many such
genes have been reported to be genetically altered in
human invasive tumours. Some gene products are
involved in proliferation (Rb, cyclin and cyclin-depend-
ent kinases), cell-cell regulation, such as p53 and cyclin
D1, and are predominantly associated with early stages
of carcinogenesis. Others, such as E-cadherin and others
adhesion molecules, are involved in cell-cell or cell-
matrix adhesion, which are likely to affects invasive
growth and metastasis [2-4].
The RB gene, located on chromosome 13q14,
encodes a 110-kd key nuclear phosphoprotein impli-
cated in the regulation of the transcription control
mechanisms mediating progression throughout G1
phase of the cell cycle [3,5]. There are different mech-
anisms like homozygous deletion, promoter hyperme-
thylation or point mutations within the coding
sequence, which leads to the inactivation of pRB by
releasing the pRB-bound E2F-members and transcrip-
tion of the S-phase genes, promoting malignant trans-
formation [4,6]. Abnormal pRB expression has been
reported in different malignant tumours, such as lung,
bladder, prostate and esophagus carcinomas and
decreased pRB immunohistochemical nuclear staining
indicating loss of Rb gene function has been reported
in a high proportion of cases [7-10]. Genetic alter-
ations involving the 13q14 region are common in
human cancers although their role in the laryngeal can-
cer progression is still unclear. 
Our purpose was to investigate 13q14 LOH and the
expression of Rb protein and their possible prognostic
value in laryngeal cancer. 
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Table 1. Characteristic of investigated group of patients with
laryngeal cancer (N=67).
Fig. 1. Representative autoradiographs from loss of heterozygosi-
ty analysis of chromosome 13q14 in laryngeal cancer. DNAs
extracted from tumour (T) and corresponding normal (N) tissues
were analysed using microsatellite marker D13S153.
Material and methods
Patients. The group of 67 patients with laryngeal cancer, surgical-
ly treated with minimum 5 years observation, was studies using
multivariate analysis (Table 1).
LOH analysis. The occurrence of homozygous deletions was
investigated by PCR. Only one tumour DNA samples showed
reduction (50%) in the intensity of the bands in the autoradiograms
when compared with the corresponding normal DNA, suggesting
the occurrence of homozygous deletion. LOH was analysed by
PCR-based techniques using two microsatellite markers, D13S263
and D13S126, flanking the Rb locus. Amplification products from
each polymorphism were fractionated by denaturing gel elec-
trophoresis, and were detected by audioradiography.
Immunohistochemistry. The archival paraffin embedded tissue
sections 5 µm thick were stained with hematoxilin and eosin (H+E)
for routine morphological examination. Immunohistochemical
staining of paraffin specimens was supervised by the use of mono-
clonal mouse antibodies IgG1 (Anti-Human Retinoblastoma Gene
Product of Dako) in dilution of 1:50. In order to expose the anti-
gen, sections were placed in the warmed citric buffer (pH=6.0) and
afterwards they were put into a microwave of 630 W for 18 min-
utes. The incubation time with the antibody was 30 minutes. For
the detection LSAB HRP+kit and DAB (3'3'diaminobenzidine) as
chromogen were used to manifest immunohistochemical reactions.
The morphometric evaluation of examined specimens was per-
formed in the light microscope (Nikon, magnification ×200 and
×400) coupled with a computer equipped with a morphometric
program. Rb protein in laryngeal cancer was quantified by calcu-
lating the index representing the ratio of cells with the positive
reaction to the entire number of the assessed tumour cells in exam-
ined area. Inactivation of Rb protein was assumed to represent the
expression in ≤10% tumour cells. 
Statistical analysis. The LOH for Rb and Rb protein expression
was estimated and statistical data were processed by the computer
program STATISTICA PL 6.0. The results of each individual fac-
tor examined were compared with age, gender, clinical staging
(TNM), histological grading, local and nodal recurrences, and
overall and disease free survival of the patients. The results were
statistically transformed (Chi-square test with Yates' correction,
Mann-Whitney test). The Kaplan and Meier model was used for
overall and disease free survival curves. Only p value of less than
0.05 were considered significant. 
Results
13q14 LOH was detected in 7/67 (10.4%) of informa-
tive tumours (Fig. 1). In the series of examined
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Fig. 2. Overall and disease free survival
in patients with laryngeal cancer accord-
ing to LOH for Rb.
tumours no correlation was found between Rb genetic
alteration (LOH) and gender, TNM staging, histologi-
cal differentiation, nodal and local recurrences
(p>0.05). There was a strong correlation between loss
of Rb and supraglottic localisation of tumour in the lar-
ynx (p<0.01).
LOH for Rb positivity was associated with a
younger age at diagnosis (<45 y.o.), but it was not sig-
nificant. By univariate analysis 13q14 LOH proved to
be significantly related to overall survival whereas it
was not related to quicker relapse (p=0.01, p>0.05
respectively) (Fig. 2). 
The genetic data were correlated with the expres-
sion of the Rb protein examined by immunohisto-
chemistry (p=0.001). All tumours with Rb-LOH were
immunohistochemically Rb-negative. 
The patterns of Rb protein expression was exclu-
sively nuclear in range between 0-85% with the
strongest intensity in proliferative tumour front (Fig. 3). 
Inactivation of Rb protein was observed in 9/67
cases (13.49%) and was significantly correlated with
polymorphism of cancer cells. More advanced poly-
morphism and differentiation of cancer cells were
related to higher Rb protein expression. We did not
find any significant correlation between Rb expression
and histological grading although in low differentiated
tumours (G3) the reduction in this protein expression
(<10% stained cancer cells) was seen more often. We
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Fig. 3. Expression of Rb protein – strong
brownish nuclear immunohistochemical
staining in laryngeal neoplastic cells, espe-
cially seen on tumour front (immunoper-
oxidase reaction, magnification ×100).
also found correlation between the size of primary
tumour (T feature) and Rb protein expression
(p=0.03), which was absent or low in advanced laryn-
geal cancers (<10%). It was noticed, that Rb expres-
sion was reduced in cases of local recurrence
(p=0.035). We found the inactivation of Rb protein
more often in cases with low histological grading (G3)
but correlations were not significant (p>0.05). There
was no significant dependence between the level of Rb
protein and gender, age of the patients, localization of
tumour in larynx, nodal and distant metastases (N and
M features), nodal recurrence or overall and disease
free survival of the patients (p>0.05) (Fig. 4).
Discussion
This study analysed the allelic status of the Rb gene
and its protein product expression in different stages of
laryngeal cancer. Consistent with previous observation
in head and neck cancer, it was found that 7 (10.4%) of
the 67 informative cases had LOH of the Rb gene [11-
13]. In our study low frequency of loss for Rb con-
firms the results obtained by Lee in head and neck can-
cer (15%) and Kannan in oral cancer (17%) [11,13].
These data are not consistent with the significant and
high frequency of allelic loss reported for the same Rb
marker in laryngeal cancer by Scholnick et al. [1].
Loss of heterozygosity at the retinoblastoma gene in
the mentioned study of laryngeal supraglottic cancer
[1) occurred at a frequency (59%) close to that found
in non small cell cancer (48%) [14] or oesophageal
cancer (54%) [10]. Nevertheless, for head and neck
cancer LOH for Rb is rather infrequent [11-13].
Although, the reason for this high percentage of LOH
for Rb in those studies might be connected with the
chosen investigated group related only to supraglottic
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Fig. 4. Overall and disease free survival in
patients with laryngeal cancer according
to Rb protein. 
laryngeal cancer cases. There is a well known a gen-
uine biologic difference between supraglottic and glot-
tic patients. Glottis and supraglottis, although anatom-
ically interconnected, are embryologically distinct
[15]. Moreover, squamous cell carcinomas originated
from these subsites, differ in terms of epidemiology,
risk factors, clinical behavior and prognosis. The
patients with supraglottic cancer usually have a poorer
prognosis, as well as more advanced (usually with
nodal metastases in the neck) and histologically
aggressive tumours than the patients with glottic
tumours [15]. In our analysis there was a strong corre-
lation between allelic loss of Rb and supraglottic local-
isation of tumour in the larynx (p=0.001). 
Changes in the expression of Rb gene, which is
localized in 13q14, correlate with the presence of Rb
mutations and they occur relatively rarely in sqamous
cell carcinoma (SCC), but it is believed that they are an
early event. It was proved that Rb gene mutation plays
a role in the mechanism of metastasis to the local
lymph nodes in the laryngeal cancer but our study did
not confirm that [16-18]. We did not find any signifi-
cant correlation between Rb LOH and clinical stage,
histological grade, local and nodal recurrences. Never-
theless, Rb LOH was demonstrated at early (2/67, I-II
stages) and advanced (5/67, III-IV stages) clinical
stages of tumour, suggesting that LOH at the Rb locus
occurs before the clonal expansion of the tumour.
Allelic imbalance of the Rb gene in our study was
associated with the decrease in pRb protein expression
as well. The connection between Rb LOH and altered
pRb expression was significant (p<0.01). Association
between LOH on 13q where Rb locus is located, and
the decreased pRb expression was observed in many
tumours, such as lung, liver, bladder, oesophagus,
endometrial cancer and chondrosarcoma [10,19-23].
Our data suggest that LOH at Rb locus plays a role in
the tumorigenesis of a subset of laryngeal cancers and
correspond with the altered expression of the pRb. In
this study the inactivation of Rb protein and 13q14
LOH were detected in almost the same percentage of
cases (10.4% and 13.4% respectively). These observa-
tions indicate that LOH for Rb presents the major
mechanism which leads to pRb inactivation. Moreover
it was found in our study that LOH of chromosomal
region 13q14 has a prognostic value in the assessment
of overall survival of patients surgically treated for
laryngeal cancer. This might suggest that Rb genetic
alteration affects not only the early development of
laryngeal cancer but also further tumour progression. 
In the presented data, the evidence of Rb gene and
protein inactivation was found in a low proportion of
laryngeal tumours examined and it may indicates Rb
as a minor target of inactivation in laryngeal cancer.
Although Volavsek et al. with their results indicated
that the loss of Rb expression in SCC cases showed a
significant association with tumour grade and that low
frequency of Rb gene inactivation might be more
important in the development of SCC than it was pre-
viously considered. They also highlighted the central
role of cyclin D1 in the regulation of the cell cycle in
head and neck cancer [24]. Cyclin D1 overexpression
(detected by IHC methods) has been described as
being able to supersede Rb-mediated growth inhibition
in SCC. The authors claim that a significant consisten-
cy between immunohistochemical and molecular
investigations of cyclin D1 and Rb indicate that pRb
immunostaining can be used as a reliable marker of the
Rb gene status [24].
The clinical relevance of pRb expression in
human tumours is still controversial: low levels of
this protein have been found to correlate with a worse
prognosis in prostate, breast, endometrial, head and
neck cancer but not in bladder and gastric cancers
[10,19,20,25-28]. In these data the loss of pRb pro-
tein was observed in 9/67 cases (13.4) and was sig-
nificantly correlated with T status (p=0.03) and local
recurrence (p=0.035). Those parameters are consid-
ered to be the predictors of poor prognosis in laryn-
geal cancer. Although, to make Rb protein expression
level more reliable prognostic factor in head and neck
carcinoma, further investigation should be made per-
haps involving detection of its phosphorylation sta-
tus. Although, all data, to our knowledge, suggest that
loss of pRb may contribute to the multistage of head
and neck carcinogenesis.
To conclude, analysis of 13q14 LOH enables the
assessment of biology of laryngeal cancer, which can
be a prognostic factor of overall survival. Although the
identity of other critical genetic loci should be revealed
by the evaluation of other chromosomal arms.
Immunohistochemical analysis of Rb protein expres-
sion in neoplastic cells made it easier to evaluate the
mechanisms of cancerogenesis in laryngeal cancer and
is closely related to genetic alteration in Rb locus. 
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